Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Galindo, M.
Right arrow Articles by Hughes, G. R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galindo, M.
Right arrow Articles by Hughes, G. R. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 1999; 38: 848-853
© 1999 British Society for Rheumatology

Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome

M. Galindo, M. A. Khamashta and G. R. V. Hughes

Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK

Correspondence to: M. A. Khamashta.

Objective. Thrombocytopenia, usually mild, is one of the clinical criteria of the antiphospholipid syndrome (APS). Rarely, this disorder requires treatment and, due to the shared characteristics with idiopathic thrombocytopenic purpura (ITP), similar rules are followed. We report our experience in patients who required splenectomy after being refractory to steroids and immunosuppressive therapy.

Methods. Fifty-five APS patients with a platelet count of <100x109 /l at least twice were analysed retrospectively. Therapeutic response or remission was considered when the platelet count was >100x109 /l after 1 month and with no relapse on stopping or tapering the steroid dose. No response or refractory disease was defined as an absence of increase in platelet count, a total count that never exceeded 50x109 /l during treatment or when the dose requirements were such that the patient developed serious side-effects.

Results. Fifty patients were classified as having secondary APS associated with systemic lupus erythematosus (SLE) and five were identified as primary APS (PAPS). Splenectomy was performed in 11 cases (20%), two PAPS and nine SLE-APS, with an average time of 28±9 months after the development of thrombocytopenia. Eight patients were initially characterized as ITP (six SLE-APS; two PAPS) with an average time of 4.4±1.1 yr until the APS diagnosis. All but two were responsive to splenectomy.

Conclusion. Splenectomy was required in 11 (20%) of the patients with APS-associated thrombocytopenia. There was a high rate of good and long-term response.

KEY WORDS: Autoimmune thrombocytopenia, Antiplatelet antibodies, Antiphospholipid antibodies, Antiphospholipid syndrome, Splenectomy, Systemic lupus erythematosus.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
J. Font, S. Jiménez, R. Cervera, M. García-Carrasco, M. Ramos-Casals, J. Campdelacreu, and M. Ingelmo
Splenectomy for refractory Evans' syndrome associated with antiphospholipid antibodies: report of two cases
Ann Rheum Dis, November 1, 2000; 59(11): 920 - 923.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.